Please turn JavaScript on
header-image

BioPharma Dive - Latest News

Subscribe to BioPharma Dive - Latest News’s news feed.

Click on “Follow” and decide if you want to get news from BioPharma Dive - Latest News via RSS, as email newsletter, via mobile or on your personal news page.

Subscription to BioPharma Dive - Latest News comes without risk as you can unsubscribe instantly at any time.

You can also filter the feed to your needs via topics and keywords so that you only receive the news from BioPharma Dive - Latest News which you are really interested in. Click on the blue “Filter” button below to get started.

Title: BioPharma Dive - Latest News

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  2.67 / day

Message History

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as having “best-in-class potential” in a competitive field.


Read full story

The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs Revlimid and Pomalyst.


Read full story

The result “pulls the rug” out from under giredestrant, according to one analyst, sparking another share selloff following disappointing obesity data last week.


Read full story

Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many developers rose on the chance of a more industry-friendly successor.


Read full story

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme and that it has struggled to sell. 


Read full story